Diakonos Oncology Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Pharma

Industry

Employee Data

  • Diakonos Oncology has 9 Employees.(i)
  • Diakonos Oncology grew their employee count by -10% last year.

Diakonos Oncology's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.7M13320%N/AN/A
#2
$13.5M676%N/AN/A
#3
$16.1M7717%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$10.1M506%N/AN/A
#6
$119.4M75738%$50MN/A
#7
$22.9M1148%N/AN/A
#8
$92.9M4628%N/AN/A
#9
$11.3M5111%N/AN/A
#10
$7M3314%N/AN/A
Add Company

What Is Diakonos Oncology?

Diakonos Oncology is pioneering cancer treatment with DOC1021, an FDA Fast Track-designated \double-loaded\ dendritic cell therapy for glioblastoma (GBM) and pancreatic cancer (PDAC). This personalized, autologous therapy has shown exceptional safety and efficacy, achieving an 88% 12-month survival rate in unmethylated GBM Phase I trials, with 38% of patients still alive after 18–29 months. With a Phase II trial launching in Q1 2025 at top GBM centers nationwide, Diakonos is reshaping outcomes for patients with the most challenging cancers.

keywords:N/A

N/A

Total Funding

9

Number of Employees

N/A

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9N/AN/A
#2
$0.7M9N/AN/A
#3
$1.1M9N/AN/A
#4
$1.1M9N/AN/A
#5
$2.6M9-10%N/A